Vaccination decisions are a routine part of daily practice, but immunity isn’t always predictable.
Across the world, many practices are looking at how antibody testing can support evidence-based vaccination protocols and informed client conversations.
Performance data for VacciCheck demonstrate strong agreement with gold standard methods (VN and HI).
In clinical studies:
- Canine Adenovirus CAV – up to 96% sensitivity / 93% specificity
- Canine Parvovirus CPV – up to 97% sensitivity / 100% specificity
- Canine Distemper CDV – up to 100% sensitivity / 92% specificity
Clinically validated through studies conducted at prestigious universities, including the University of Wisconsin-Madison, University of Florida, Cornell University, Colorado State University, and others.
Titre testing isn’t about replacing vaccination, it’s about adding objective immunity data to support tailored preventive care.
Canine VacciCheck Performance
| Virus | Sample Size | Sensitivity | Specificity | Gold Standard Method |
|---|---|---|---|---|
| Canine Adenovirus CAV | 183 | 96% | 90% | Virus Neutralization (VN) |
| Canine Parvovirus CPV | 563 | 97% | 94% | Hemagglutination Inhibition (HI) |
| Canine Distemper CDV | 563 | 96% | 88% | Virus Neutralization (VN) |
Feline VacciCheck Performance
| Virus | Sample Size | Sensitivity | Specificity | Gold Standard Method |
|---|---|---|---|---|
| Feline Calici Virus FCV | 344 | 90% | 91% | Virus Neutralization (VN) |
| Feline Herpesvirus FHV | 344 | 93% | 96% | Virus Neutralization (VN) |
| Panleukopenia Virus FPLV | 344 | 89% | 89% | Hemagglutination Inhibition (HI) |
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
